Why the study?
Does isoproterenol-induced cardiac injury increase serum cardiac troponin I levels in a dose- and route-dependent manner in rats?
Does isoproterenol-induced cardiac injury increase serum cardiac troponin I levels in a dose- and route-dependent manner in rats?
The study provides preclinical evidence supporting cTnI as a sensitive biomarker for cardiac injury, demonstrating dose- and route-dependent increases following isoproterenol administration in rats.
Supports cTnI as sensitive marker in rat ISO models; leaves open translation to clinical cardiac injury detection.
The current studies demonstrate the effect of low-dose intraperitoneal (IP) administration of isoprotenerol (ISO) and subcutaneous (SC) versus IP routes of administration of ISO on serum cardiac troponin I (cTnI) levels in female Hanover Wistar rats, providing additional evidence to support acceptance of cTnI as a cardiac biomarker. At 2 hr postdosing with 0-500 microg/kg ISO, mean serum cTnI levels were increased in a dose-related fashion at > or =10 microg/kg with no evidence of cardiac pathology. At 24 h, cTnI concentrations were generally at control levels, but histologic cardiomyocyte injury was evident in a proportion of the animals given > or =10 microg/kg. In a second experiment, rats given SC ISO at 5,000 microg/kg and necropsied at 0, 1, 2, and 4 hr postdosing had higher levels of serum cTnI than animals given the same dose IP.
No takes yet. Share an insight, caveat, or question.
Brady et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: